Medicina
Departamento
Institute Curie
París, FranciaPublicaciones en colaboración con investigadores/as de Institute Curie (27)
2022
-
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications biology, Vol. 5, Núm. 1, pp. 1061
-
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology, Vol. 32
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362
2021
-
21-gene assay to inform chemotherapy benefit in node-positive breast cancer
New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347
-
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
The Lancet Oncology, Vol. 22, Núm. 4, pp. 489-498
-
Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival
International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894
2020
-
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness
Cancer Research, Vol. 80, Núm. 3, pp. 624-638
-
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 26, Núm. 15, pp. 3947-3957
-
Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
JAMA Oncology, Vol. 6, Núm. 8, pp. 1218-1230
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics, Vol. 52, Núm. 1, pp. 56-73
-
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Annals of Oncology, Vol. 31, Núm. 8, pp. 1001-1010
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Genetic Epidemiology, Vol. 44, Núm. 5, pp. 442-468
2019
-
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study
Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811
-
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Nature Communications, Vol. 10, Núm. 1
-
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
npj Breast Cancer, Vol. 5, Núm. 1
2018
-
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis
Journal of the National Cancer Institute, Vol. 110, Núm. 6, pp. 560-567
2017
-
Identification of miRSNPs associated with the risk of multiple myeloma
International Journal of Cancer, Vol. 140, Núm. 3, pp. 526-534
-
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Nature Genetics, Vol. 49, Núm. 12, pp. 1767-1778